APA (7th ed.) Citation

Jabbour, E., Martinelli, G., Vignetti, M., Kantarjian, H. M., Gómez Almaguer, D., Minami, Y., . . . Ribera, J. M. (2022). PB1762: Ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study. Wolters Kluwer Health.

Chicago Style (17th ed.) Citation

Jabbour, E., et al. PB1762: Ponatinib Versus Imatinib with Reduced-intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–positive (ph+) Acute Lymphoblastic Leukemia (all): Phallcon Study. Wolters Kluwer Health, 2022.

MLA (9th ed.) Citation

Jabbour, E., et al. PB1762: Ponatinib Versus Imatinib with Reduced-intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–positive (ph+) Acute Lymphoblastic Leukemia (all): Phallcon Study. Wolters Kluwer Health, 2022.